Thermo Fisher Webinar: Accelerating Biologics Development by Leveraging Integrated Solutions and Technology Innovation

Event-Datum: 02.07.2020

15:00 – 16:30 CET

Registration Link

This online event is geared towards companies developing biological drugs that are either in the early development or clinical phases.
Recent global challenges have forced biotech companies, especially new and emerging companies, who are increasingly worried about handling abrupt disruptions to their supply chain, to re-think their outsourced development, manufacturing, and clinical trials strategy to get their molecule successfully to the market.
The event will have Subject Matter Experts from Thermo Fisher Scientific, Pharma Services Group presenting novel solutions that can help accelerate biologics development and integrated solutions that can streamline the complicated drug development process and help mitigate the inherent risks associated with bringing a molecule to the market.

Isabel Hervias Business Development Executive – Biologics, Spain
Isabel is a BDE representing large molecule Drug Substance capabilities and expertise for Thermo Fisher Scientific. Isabel has both a scientific and a business background and has been supporting biotech and pharma organizations for the past seven years in finding tailored solutions to bring their molecules from the lab to clinic and market.

Augusto Cabral Senior Account Manager DACH, Switzerland
Augusto is a liaison between expertise and capabilities of Thermo Fisher’s Clinical Trial Division and its partners and clients involved in clinical development and operations. He has an academic background in Pharmacy and Protein Chemistry and has spent the past ten years supporting and advising organizations in various phases of pharmaceutical development by developing tailored and reliable clinical supply chain solutions.

Jeff Hou Manager, Cell Culture Development, Princeton, NJ
Jeff currently serves as a biologics subject matter expert for Thermo Fisher Scientific’s drug substance division. With a background in cell line and cell culture development, Jeff has broad knowledge and experience relating to development of biologics and its path through development and manufacturing. During the last four years at Thermo Fisher Scientific, Jeff has developed a significant insight into balancing the cost, time and quality of a drug lifecycle under a CMO, from preclinical to commercial. Jeff’s story.

Simon Caviezel Program Director EMEA, Switzerland
Simon is a program director in EMEA for Thermo Fisher Scientific’s Clinical Supply Optimization service. Bringing more than nine years of industry experience to the business, Simon has a broad knowledge and a wealth of experience managing clinical study supply on both local and global trials. During his time in the industry, Simon has developed a thorough understanding of how supply chain planning must align with risk mitigation to be able to reliably provide the right product to the right patient at the right time.